[1] [2] The pivotal SURPASS clinical trial programme, which evaluated tirzepatide's efficacy and safety in thousands of patients with type 2 diabetes, did not identify lymph node swelling as a recognised adverse effect
Data were extracted into a standardized table capturing Study design, Sample size and population, Intervention or exposure (e.g., antioxidant agent, mitochondrial marker), Outcomes (e.g., pain, fatigue, oxidative markers), Key findings relevant to the PICO questions above
Semaglutide activates GLP-1 receptors, improving metabolic status and stabilizing blood glucose levels
[Screenshot asset suggestion: A comparison table or bar chart showing the percentage of weight loss across different GLP-1 and multi-agonist medications.] Retatrutide vs Semaglutide (Wegovy and Ozempic) Semaglutide was the first molecule to truly change the weight loss conversation